{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:12:38Z","timestamp":1790399558285,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd011884","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000}}],"reference-count":101,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011884.pub2","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T09:41:21Z","timestamp":1526031681000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia"],"prefix":"10.1002","volume":"2018","author":[{"given":"Myrto T","family":"Samara","sequence":"first","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaninger Stra\u00dfe 22 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Klupp","sequence":"additional","affiliation":[{"name":"Technical University Munich; Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar; Ismaninger Str. 22 M\u00fcnchen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Helfer","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaninger Stra\u00dfe 22 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp H","family":"Rothe","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaninger Stra\u00dfe 22 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaninger Stra\u00dfe 22 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaninger Stra\u00dfe 22 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,11]]},"reference":[{"key":"10.1002\/14651858.CD011884.pub2-BIB0001|cit1","first-page":"53","article-title":"Schizophrenia: alternative neuroleptic strategies","volume-title":"The Neuroleptic-Nonresponsive Patient: Characterization and Treatment","author":"Johns","year":"1990"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0920-9964(93)90535-Q","article-title":"Alternative strategies for treating neuroleptic nonresponsive patients","volume":"9","author":"Kane","year":"1993","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD011884.pub2-BIB0003|cit3","first-page":"309","article-title":"Treatment of neuroleptic-resistant schizophrenic relapse","volume":"29","author":"Kinon","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"issue":"9","key":"10.1002\/14651858.CD011884.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.euroneuro.2013.04.010","article-title":"Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching","volume":"23","author":"Agid","year":"2013","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011884.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0924-977X(95)90593-3","article-title":"A randomized double-bind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia","volume":"5","author":"Bondolfi","year":"1995","journal-title":"European Neuropsychopharmacology"},{"issue":"1-2","key":"10.1002\/14651858.CD011884.pub2-BIB0006|cit6","first-page":"144","article-title":"Plasma levels and dosing strategies in schizophrenic patients receiving clozapine","volume":"15","author":"Buckley","year":"1995","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD011884.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/01.jcp.0000096246.29231.73","article-title":"The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind, crossover study","volume":"23","author":"Conley","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0008|cit8","first-page":"481","article-title":"Ziprasidone in treatment - resistant schizophrenia: long - term efficacy and tolerability","volume":"31","author":"Dunn","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD011884.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0920-9964(03)80480-2","article-title":"Ziprasidone versus chlorpromazine in treatment-refractory schizophrenia","volume":"60","author":"Khanna","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD011884.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0920-9964(03)80460-7","article-title":"Randomized assessment of strategies for switching patients with sub-optimal treatment outcomes from olanzapine to risperidone","volume":"60","author":"Ganguli","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD011884.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JCP.0b013e3182977308","article-title":"High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: The ZEBRAS study","volume":"33","author":"Goff","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0012|cit12","unstructured":"NCT00403546 High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms clinicaltrials.gov\/show\/NCT00403546"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011884.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1016\/S0924-977X(07)70663-6","article-title":"Cognitive effects of ziprasidone and clozapine: results from an 18-week double-blind trial","volume":"17","author":"Harvey","year":"2007","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011884.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.psychres.2012.01.006","article-title":"A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone","volume":"198","author":"Hatta","year":"2012","journal-title":"Psychiatry Research"},{"issue":"2-3","key":"10.1002\/14651858.CD011884.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.schres.2010.02.670","article-title":"A double blind, placebo controlled study of the safety and tolerability of quetiapine 1200 mg\/d versus 800 mg\/d in patients with persistent symptoms of schizophrenia or schizoaffective disorder","volume":"117","author":"Honer","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD011884.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4088\/JCP.10m06194","article-title":"A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder","volume":"73","author":"Honer","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD011884.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/0006-3223(94)90844-3","article-title":"Random assignment to 3 haloperidol plasma-levels for acute-psychosis","volume":"35","author":"Janicak","year":"1994","journal-title":"Biological Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD011884.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011884.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v68n0206","article-title":"Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine","volume":"68","author":"Kane","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD011884.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1185\/03007995.2013.816277","article-title":"Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents","volume":"29","author":"Kim","year":"2013","journal-title":"Current Medical Research and Opinion"},{"issue":"2-3","key":"10.1002\/14651858.CD011884.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.schres.2010.02.088","article-title":"Differences between early responders and early non-responders to atypical antipsychotics on symptom and functional outcomes in the treatment of schizophrenia","volume":"117","author":"Kinon","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011884.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1016\/S0924-977X(09)70213-5","article-title":"Early response as a response predictor: Use of individual variability in clinical trials","volume":"19","author":"Kinon","year":"2009","journal-title":"European Neuropsychopharmacology"},{"issue":"1-3","key":"10.1002\/14651858.CD011884.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.schres.2009.12.013","article-title":"Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia","volume":"118","author":"Kinon","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD011884.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/npp.2009.164","article-title":"Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia","volume":"35","author":"Kinon","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0025|cit25","unstructured":"Kinon BJ Stauffer V Ascher-Svanum H Tomori O Kollack-Walker S Predicting response to risperidone treatment through identification of early-onset of antipsychotic drug action in schizophrenia Proceedings of the 161st Annual Meeting of the American Psychiatric Association Washington DC"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0026|cit26","unstructured":"Stauffer V Chen L Ascher-Svanum H Kollack-Walker S Zhou W Kapur S Switching antipsychotic drugs enhances improvement in patients who show lack of an early response to their initial antipsychotic therapy Proceedings of the 162nd Annual Meeting of the American Psychiatric Association San Francisco, CA"},{"issue":"2","key":"10.1002\/14651858.CD011884.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/JCP.0b013e31820f4fe0","article-title":"A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg\/d for patients with treatment-resistant schizophrenia or schizoaffective disorder","volume":"31","author":"Lindenmayer","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD011884.pub2-BIB0028|cit28","first-page":"Article: 1046","article-title":"Switching to lurasidone in patients with schizophrenia: Tolerability and effectiveness at 6 weeks and 6 months","volume":"28","author":"McEvoy","year":"2013","journal-title":"European Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011884.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4088\/JCP.12m07992","article-title":"Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: A randomized, 6-week, open-label study","volume":"74","author":"McEvoy","year":"2013","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011884.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1016\/S0924-977X(13)70770-3","article-title":"Switching to lurasidone in patients with schizophrenia: tolerability and effectiveness at 6 weeks and 6 months","volume":"23","author":"McEvoy","year":"2013","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0031|cit31","first-page":"S343","article-title":"Switching to lurasidone in patients with schizophrenia: Tolerability and effectiveness at 6 weeks and 6 months","volume":"39","author":"McEvoy","year":"2013","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0032|cit32","unstructured":"NCT00161018 New antipsychotic strategies: quetiapine and risperidone vs. fluphenazine in treatment resistant schizophrenia clinicaltrials.gov\/show\/NCT00161018"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0033|cit33","unstructured":"NCT00191555 Efficacy study of switching stabilized schizophrenic patients from conventional to atypical antipsychotic treatment clinicaltrials.gov\/ct2\/show\/NCT00191555"},{"issue":"Suppl B","key":"10.1002\/14651858.CD011884.pub2-BIB0034|cit34","first-page":"133","article-title":"Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia","volume":"55","author":"Potkin","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD011884.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.schres.2009.02.017","article-title":"Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study","volume":"110","author":"Sacchetti","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"11","key":"10.1002\/14651858.CD011884.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.156.11.1744","article-title":"Double blind study of clozapine dose response in chronic schizophrenia","volume":"156","author":"Simpson","year":"1999","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011884.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-007-0872-2","article-title":"How effective is it to sequentially switch among olanzapine, quetiapine and risperidone? - A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting","volume":"195","author":"Suzuki","year":"2007","journal-title":"Psychopharmacology [psychopharmacologia]"},{"issue":"5","key":"10.1002\/14651858.CD011884.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4088\/JCP.v64n0514","article-title":"Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia","volume":"64","author":"Weiden","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD011884.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1176\/ajp.156.9.1374","article-title":"Risperidone in treatment-refractory schizophrenia","volume":"156","author":"Wirshing","year":"1999","journal-title":"American Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD011884.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","article-title":"Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected","volume":"60","author":"Agid","year":"2003","journal-title":"Archives of General Psychiatry"},{"issue":"7066","key":"10.1002\/14651858.CD011884.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0042|cit42","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1987"},{"issue":"7","key":"10.1002\/14651858.CD011884.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1982.04290070025006","article-title":"Negative vs. positive schizophrenia: Definition and validation","volume":"39","author":"Andreasen","year":"1982","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011884.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011884.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archpsyc.1988.01800250095013","article-title":"Significance of neuroleptic dose and plasma level in the treatment of psychoses","volume":"45","author":"Baldessarini","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"489-516","DOI":"10.1002\/9780470987353.ch26","article-title":"Treatment-resistant schizophrenia","volume-title":"Schizophrenia","author":"Barnes","year":"2003"},{"issue":"7108","key":"10.1002\/14651858.CD011884.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011884.pub2-BIB0048|cit48","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0049|cit49","first-page":"2125","article-title":"Employment and the associated impact on quality of life in people diagnosed with schizophrenia","volume":"11","author":"Bouwmans","year":"2015","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"1","key":"10.1002\/14651858.CD011884.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0051|cit51","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium Cape Town The Cochrane Collaboration"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0052|cit52","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"3","key":"10.1002\/14651858.CD011884.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"6","key":"10.1002\/14651858.CD011884.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011884.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/eb-2014-101813","article-title":"Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective","volume":"17","author":"Dold","year":"2014","journal-title":"Evidence-based Mental Health"},{"issue":"19","key":"10.1002\/14651858.CD011884.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD011884.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011884.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD011884.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/15622970510030090","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment ofschizophrenia, Part 1: acute treatment of schizophrenia","volume":"6","author":"Falkai","year":"2005","journal-title":"World Journal of Biological Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011884.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1-3","key":"10.1002\/14651858.CD011884.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.schres.2010.10.016","article-title":"Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials","volume":"126","author":"Furukawa","year":"2011","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD011884.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"American Journal of Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD011884.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0064|cit64","article-title":"ECDEU assessment manual for psychopharmacology-Revised","volume-title":"ECDEU assessment manual for psychopharmacology-Revised","author":"Guy","year":"1976"},{"issue":"5","key":"10.1002\/14651858.CD011884.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World Journal of Biological Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD011884.pub2-BIB0066|cit66","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011883","article-title":"Increasing antipsychotic dose for non response in schizophrenia","author":"Helfer","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7414","key":"10.1002\/14651858.CD011884.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0068|cit68","unstructured":"Higgins JP Green S Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0069|cit69","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0070|cit70","doi-asserted-by":"crossref","unstructured":"Howes OD McCutcheon R Agid O de Bartolomeis A van Beveren NJ Birnbaum ML Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology American Journal of Psychiatry 2017 216 29","DOI":"10.1176\/appi.ajp.2016.16050503"},{"issue":"1","key":"10.1002\/14651858.CD011884.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD011884.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00406-006-0683-1","article-title":"Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders","volume":"257","author":"J\u00e4ger","year":"2007","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"10","key":"10.1002\/14651858.CD011884.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1396-408","DOI":"10.1016\/S0006-3223(99)00059-1","article-title":"Pharmacologic treatment of schizophrenia","volume":"46","author":"Kane","year":"1999","journal-title":"Biological Psychiatry"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD011884.pub2-BIB0074|cit74","first-page":"5","article-title":"The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary","volume":"64","author":"Kane","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0075|cit75","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"9","key":"10.1002\/14651858.CD011884.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00023210-200418090-00005","article-title":"Dose response and atypical antipsychotics in schizophrenia","volume":"18","author":"Kinon","year":"2004","journal-title":"CNS Drugs"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011884.pub2-BIB0077|cit77","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD011884.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD011884.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011884.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0033-1335405","article-title":"Pharmacological treatment of schizophrenia","volume":"81","author":"Leucht","year":"2013","journal-title":"Fortschritte der Neurologie-Psychiatrie"},{"issue":"3","key":"10.1002\/14651858.CD011884.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbv019","article-title":"The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics","volume":"41","author":"Leucht","year":"2015","journal-title":"Schizophrenia Bulletin"},{"issue":"12","key":"10.1002\/14651858.CD011884.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1209-23","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011884.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/157015909790031229","article-title":"Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I","volume":"7","author":"Miller","year":"2009","journal-title":"Current Neuropharmacology"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"285","author":"Moher","year":"2001","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"10.1002\/14651858.CD011884.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijsu.2011.10.001","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"10","author":"Moher","year":"2012","journal-title":"International Journal of Surgery (London, England)"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"3","key":"10.1002\/14651858.CD011884.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/archpsyc.62.3.247","article-title":"The lifetime risk of suicide in schizophrenia: a reexamination","volume":"62","author":"Palmer","year":"2005","journal-title":"Archives of General Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011884.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","article-title":"Early improvement as a Predictor of later response to antipsychotics in schizophrenia: a diagnostic test review","volume":"172","author":"Samara","year":"2015","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0092|cit92","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"5","key":"10.1002\/14651858.CD011884.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/clinchem\/44.5.914","article-title":"Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication","volume":"44","author":"Steijns","year":"1998","journal-title":"Clinical Chemistry"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0095|cit95","unstructured":"Sterne JA Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD011884.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"10","key":"10.1002\/14651858.CD011884.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2217\/pgs.12.86","article-title":"Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective","volume":"13","author":"Vijayan","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"9859","key":"10.1002\/14651858.CD011884.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011884.pub2-BIB0099|cit99","doi-asserted-by":"crossref","unstructured":"Xia J Adams CE Bhagat N Bhagat V Bhoopathi P El-Sayeh H Loss to outcomes stakeholder survey: the LOSS study Schizophrenia Research 2010 278","DOI":"10.1016\/j.schres.2010.02.451"},{"issue":"7","key":"10.1002\/14651858.CD011884.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1176\/appi.ajp.2009.09040598","article-title":"D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis","volume":"167","author":"Zhang","year":"2010","journal-title":"American Journal of Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD011884.pub2-BIB0101|cit101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011884","article-title":"Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia","author":"Samara","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011884.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T13:24:21Z","timestamp":1661261061000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD011884.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,5,11]]},"references-count":101,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011884.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,11]]}}}